GANX
Gain Therapeutics, Inc.
$1.79
+2.29%
$76.4M
No data for this timeframe.
Vol
Market Cap$76.4M
Cap SizeMicro Cap
Inst. Holders19 funds
Inst. Value$8.3M
Inst. Activity1 buys / 1 sells
Reddit Sentiment54° Neutral
SEC Reports3
Press Releases2
Recent Activity
Jun 10, 2026
other
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
<p align="left">BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq:
May 26, 2026
SEC
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 in Parkins
8-K — Impact 5/10
May 11, 2026
SEC
Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat is marginal for a pr
PRESS-RELEASE — Impact 4/10
Apr 28, 2026
SEC
Gain Therapeutics filed definitive additional proxy materials (DEFA14A) for its 2026 annual meeting, recommending stockh
DEFA14A — Impact 3/10
Mar 24, 2026
Insider
Fuggetta Gianluca was granted 50,000 shares
See Remark
Mar 24, 2026
Insider
Mack Gene was granted 200,000 shares
CEO, President
Inst.
COMMONWEALTH EQUITY SERVICES, LLC — DOUBLED
29,703 shares ($57.6K)
Inst.
GROUP ONE TRADING LLC — NEAR_EXIT
6,404 shares ($12.4K)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$7.20 (Dec 2025)
Current $1.79
Low $5.00
Median $8.00
High $8.00
5 analysts
$5.00
$8.00
Analyst Ratings
4Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.15 ▼ -2.3% | $-0.18 — $-0.13 | 21% YoY | 4 |
| Next Q | $-0.16 ▲ +3.6% | $-0.21 — $-0.13 | -5% YoY | 4 |
| Current FY | $-0.60 | $-0.79 — $-0.51 | 1% YoY | 4 |
| Next FY | $-0.60 ▲ +3.7% | $-0.74 — $-0.48 | 0% YoY | 3 |
Latest Reports
BULLISH
8-K
5/10
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of GT-02287 in Parkins
May 26, 2026
NEUTRAL
PRESS-RELEASE
4/10
Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat is marginal for a pr
May 11, 2026
MIXED
Press
6/10
Gain Therapeutics reported financial results for 2025, showing a slight reduction in net loss to $20.2M from $20.4M in 2
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MARSHALL WACE, LLP | $3.4M | DOUBLED |
| JONES FINANCIAL COMPANIES LLLP | $1.2M | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $836.7K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $775.8K | — |
| VANGUARD FIDUCIARY TRUST CO | $446.2K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 24, 2026 | Fuggetta Gianluca | A | $0.00 |
| Mar 24, 2026 | Mack Gene | A | $0.00 |
Reddit Sentiment
54°▲
Neutral
Bearish
Neutral
Bullish
19 institutional holders with $8.3M total value (4,334,960 shares) as of 2026-Q1. Top holders: MARSHALL, JONES, SUSQUEHANNA.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 1,769,788 | $3.4M | 41.2% | DOUBLED +849.3% |
| 2 | JONES FINANCIAL COMPANIES LLLP | 631,615 | $1.2M | 13.9% | — |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 431,267 | $836.7K | 10.0% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 399,886 | $775.8K | 9.3% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 229,979 | $446.2K | 5.4% | — |
| 6 | BlackRock, Inc. | 225,046 | $436.6K | 5.2% | ADD +80.4% |
| 7 | Cresset Asset Management, LLC | 160,000 | $310.4K | 3.7% | — |
| 8 | STATE STREET CORP | 157,537 | $305.6K | 3.7% | ADD +72.9% |
| 9 | MORGAN STANLEY | 139,652 | $270.9K | 3.2% | DOUBLED +103.5% |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38,300 | $74.3K | 0.9% | — |
| 11 | CITADEL ADVISORS LLC | 31,400 | $60.9K | 0.7% | DOUBLED +130.9% |
| 12 | COMMONWEALTH EQUITY SERVICES, LLC | 29,703 | $57.6K | 0.7% | DOUBLED +134.2% |
| 13 | CITADEL ADVISORS LLC | 24,900 | $48.3K | 0.6% | DOUBLED +130.9% |
| 14 | Vanguard Global Advisers, LLC | 18,376 | $35.6K | 0.4% | — |
| 15 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 15,556 | $28.8K | 0.3% | — |
| 16 | CITADEL ADVISORS LLC | 14,500 | $28.1K | 0.3% | DOUBLED +130.9% |
| 17 | WELLS FARGO & COMPANY/MN | 11,050 | $21.4K | 0.3% | — |
| 18 | GROUP ONE TRADING LLC | 6,404 | $12.4K | 0.1% | NEAR_EXIT -88.2% |
| 19 | CITIGROUP INC | 1 | $2.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| COMMONWEALTH EQUITY SERVICES, LLC | DOUBLED | 12,685 | 29,703 | +134.2% | $57.6K | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 54,159 | 6,404 | -88.2% | $12.4K | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 175,107 | 1,662,293 | +849.3% | $5.4M | 2025-Q4 |
| BlackRock, Inc. | ADD | 116,184 | 209,579 | +80.4% | $674.8K | 2025-Q4 |
| STATE STREET CORP | ADD | 91,137 | 157,537 | +72.9% | $507.3K | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 16,775 | 54,159 | +222.9% | $174.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 126,100 | 17,400 | -86.2% | $56.0K | 2025-Q4 |
| HRT FINANCIAL LP | DOUBLED | 19,717 | 55,679 | +182.4% | $179.00 | 2025-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 161,816 | 373,558 | +130.9% | $661.2K | 2025-Q3 |
| MARSHALL WACE, LLP | TRIM | 276,433 | 175,107 | -36.7% | $309.9K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 76,512 | 155,675 | +103.5% | $275.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 32,635 | 140,677 | +331.1% | $249.0K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 94,000 | 126,100 | +34.1% | $223.2K | 2025-Q3 |
| STATE STREET CORP | ADD | 71,137 | 91,137 | +28.1% | $161.3K | 2025-Q3 |
| GROUP ONE TRADING LLC | DOUBLED | 6,401 | 16,775 | +162.1% | $29.7K | 2025-Q3 |
| Gotham Asset Management, LLC | ADD | 153,984 | 245,896 | +59.7% | $5.4M | 2025-Q2 |
| VANGUARD GROUP INC | DOUBLED | 254,990 | 534,352 | +109.6% | $961.8K | 2025-Q2 |
| MARSHALL WACE, LLP | ADD | 196,026 | 276,433 | +41.0% | $497.6K | 2025-Q2 |
| MARSHALL WACE, LLP | DOUBLED | 91,738 | 196,026 | +113.7% | $374.4K | 2025-Q1 |
| Gotham Asset Management, LLC | TRIM | 334,592 | 158,155 | -52.7% | $3.7M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 4,800 | 88,512 | +1744.0% | $191.2K | 2024-Q4 |
| STATE STREET CORP | DOUBLED | 34,437 | 71,137 | +106.6% | $153.7K | 2024-Q4 |
| UBS Group AG | DOUBLED | 8,455 | 35,227 | +316.6% | $76.1K | 2024-Q4 |
| MORGAN STANLEY | ADD | 3,300 | 4,800 | +45.5% | $8.5K | 2024-Q3 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 7,401 | 1,401 | -81.1% | $2.5K | 2024-Q3 |
2 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 24, 2026 | Fuggetta Gianluca | See Remark | AWARD | 50,000 | — | — |
| Mar 24, 2026 | Mack Gene | CEO, President | AWARD | 200,000 | — | — |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 4.0/10.
BULLISH
8-K
5/10
Gain Therapeutics announced interim clinical and biomarker data from Part 2 of its Phase 1b study of
May 26, 2026
NEUTRAL
PRESS-RELEASE
4/10
Gain Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.14 by 7.1%, but the beat
May 11, 2026
NEUTRAL
DEFA14A
3/10
Gain Therapeutics filed definitive additional proxy materials (DEFA14A) for its 2026 annual meeting,
Apr 28, 2026
Historical analyst distribution (last covering-analyst action Dec 2025): 91% buy across 11 analysts — 4 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$7.20 mean target (Dec 2025)
$5.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.79 |
| Target Low | $5.00 |
| Target Mean | $7.20 |
| Target Median | $8.00 |
| Target High | $8.00 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.15 | $-0.18 | $-0.13 | 21.0% | -2.3% | — | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.16 | $-0.21 | $-0.13 | -5.0% | +3.6% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.60 | $-0.79 | $-0.51 | 1.2% | +0.4% | 1↑ 1↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-0.60 | $-0.74 | $-0.48 | 0.4% | +3.7% | 1↑ 1↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.150 | |
| 7d ago | $-0.140 | -0.010 |
| 30d ago | $-0.147 | -0.003 |
| 60d ago | $-0.150 | |
| 90d ago | $-0.163 | +0.013 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
54°
Neutral
Bearish
Neutral
Bullish
32 mentions
10 bullish
7 bearish
21 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 26, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 26, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 4 | 44° Neutral | 0 | 1 | 4 |
| May 20, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| May 12, 2026 | 3 | 36° Cool | 0 | 2 | 3 |
| May 12, 2026 | 3 | 36° Cool | 0 | 2 | 3 |
| May 6, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| May 6, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 30, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 30, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 29, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Apr 29, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 27, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 18, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 18, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 2, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
GANX — Honest Look at the Risk Profile. This Is a Binary Clinical Bet With a Ticking Cash Clock.
▲ 1
💬 1
⚡ 0.5
GANX — The Catalyst Timeline For the Rest of 2026
▲ 1
💬 1
⚡ 0.5
GANX Q1: Net loss widened. R&D and G&A up. Timelines intact (Q2 IND, Q3 Phase 2, Q4 more data). That's the real story.
▲ 1
💬 1
⚡ 0.2
World Parkinson's Congress right after. Back to back conferences maximize exposure for a small biotech.
▲ 1
💬 0
⚡ 0.5
MJFF backing + Silverstein backing + conference presentations + biomarker data. GANX checking boxes for a clinical stage name.
▲ 1
💬 1
⚡ 0.5
GANX breakdown: GT-02287 (Parkinson's, GBA1), Phase 1b biomarker data (81% GluSph drop), now two major conferences in May.
▲ 1
💬 1
⚡ 0.5
$GANX Announcement - Currently Down 23%
▲ 1
💬 1
⚡ 0.5
Jun 10, 2026
other
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
<p align="left">BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage
Jun 9, 2026
short_volume
Short Volume: GANX — 73.9% short (0.6M / 0.8M)
Short: 564,149 | Exempt: 5,895 | TRF Vol: 763,378 | Short Ratio: 73.9% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: GANX — 62.4% short (0.3M / 0.5M)
Short: 329,803 | Exempt: 0 | TRF Vol: 528,189 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
GANX Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
<p>BETHESDA, Md., May 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology
Apr 24, 2026
other
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
<p>BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnolo
Mar 26, 2026
earnings
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
<p>BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnolo
Mar 19, 2026
other
Gain Therapeutics to Present at the 38th Annual ROTH Conference
<p>BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnolo
Mar 19, 2026
earnings_calendar
GANX Q4 2025 Earnings After Market Close — 2026-03-19
Mar 18, 2026
fda
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
<p align="center"><em>Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with